2026-04-17T02:59:39Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/60582025-10-24T10:32:27Zcom_2072_378070com_2072_378040col_2072_378092

00925njm 22002777a 4500 dc Suy Franch, Anna author Garcia Ruiz, Itziar author Carbonell Socias, Melchor author García Manau, Pablo author Rodó Rodríguez, Carlota author Maiz Elizaran, Nerea author Sulleiro Igual, Elena author Esperalba Esquerra, Juliana author Fernández Hidalgo, Nuria author Frick, Marie Antoinette author Camba Longueira, Fátima author Pumarola Suñé, Tomàs author Carreras Moratonas, Elena author Antón Pagarolas, Andrés author 2021-06-11T12:44:52Z 2021-06-11T12:44:52Z 2021-01-22 Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Embaràs; Transmissió vertical Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Embarazo; Transmisión vertical Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Pregnancy; Vertical transmission Background The Coronavirus Disease 2019 (COVID-19) is a novel disease which has been having a worldwide affect since December 2019. Evidence regarding the effects of SARS-CoV-2 during pregnancy is conflicting. The presence of SARS-CoV-2 has been demonstrated in biological samples during pregnancy (placenta, umbilical cord or amniotic fluid); however, maternal and fetal effects of the virus are not well known. Methods Descriptive, multicentre, longitudinal, observational study in eight tertiary care hospitals throughout Spain, that are referral centres for pregnant women with COVID-19. All pregnant women with positive SARS-CoV-2 real-time reverse transcriptase polymerase chain reaction during their pregnancy or 14 days preconception and newborns born to mothers infected with SARS-CoV-2 will be included. They will continue to be followed up until 4 weeks after delivery. The aim of the study is to investigate both the effect of COVID-19 on the pregnancy, and the effect of the pregnancy status with the evolution of the SARS-CoV-2 disease. Other samples (faeces, urine, serum, amniotic fluid, cord and peripheral blood, placenta and breastmilk) will be collected in order to analyse whether or not there is a risk of vertical transmission and to describe the behaviour of the virus in other fluids. Neonates will be followed until 6 months after delivery to establish the rate of neonatal transmission. We aim to include 150 pregnant women and their babies. Ethics approval will be obtained from all the participating centres. Discussion There is little information known about COVID-19 and its unknown effects on pregnancy. This study will collect a large number of samples in pregnant women which will allow us to demonstrate the behaviour of the virus in pregnancy and postpartum in a representative cohort of the Spanish population. The study has been awarded with a Spanish Government grant (Instituto de Salud Carlos III: COV20/00188). It covers the expenses for transporting, processing and analyzing samples, database creation and maintenance, and hiring support staff. http://hdl.handle.net/11351/6058 COVID-19 (Malaltia) - Transmissió Embaràs HEALTH CARE::Environment and Public Health::Public Health::Disease Transmission, Infectious::Infectious Disease Transmission, Vertical DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections PHENOMENA AND PROCESSES::Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Reproduction::Pregnancy ATENCIÓN DE SALUD::ambiente y salud pública::salud pública::transmisión de una enfermedad infecciosa::transmisión vertical de enfermedades infecciosas ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus FENÓMENOS Y PROCESOS::fenómenos fisiológicos reproductivos y urinarios::fenómenos fisiológicos de la reproducción::reproducción::embarazo Gestation and COVID-19: clinical and microbiological observational study (Gesta-COVID19)